Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.40 |
| ▸ | TDO2 | P48775 | 12/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 2/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803228 | 0.80 | IDO1 (0.38) | IDO1TDO2IDO2CHRM2ADRA2A | |
| SCHEMBL2839765 | 0.79 | HTT (0.41) | IDO1TDO2IDO2CHRM2ADRA2A | |
| SCHEMBL10141173 | 0.77 | IDO1 (0.36) | IDO1TDO2IDO2CHRM2ADRA2A | |
| SCHEMBL7716632 | 0.74 | HTT (0.41) | IDO1TDO2IDO2CHRM2ADRA2A | |
| SCHEMBL7718706 | 0.69 | IDO1 (0.42) | IDO1TDO2IDO2CHRM2ADRA2A | |
| SCHEMBL2843916 | 0.68 | PTGS2 (0.42) | — | |
| SCHEMBL6230663 | 0.68 | HRH1 (0.39) | CHRM2ADRA2ACHRM1SLC6A2ADRA1A | |
| SCHEMBL6282856 | 0.68 | THRB (0.39) | ADRA2ASLC6A2SLC6A3HTTHTR2A | |
| SCHEMBL1417280 | 0.68 | THRB (0.39) | ADRA2ASLC6A2SLC6A3HTTHTR2A | |
| SCHEMBL29243149 | 0.67 | DPP4 (0.33) | IDO1TDO2SLC6A2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-01-02 | — | — | US | disclosed |
| US-20230203509-A1 | TREM COMPOSITIONS AND METHODS RELATING THERETO | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2023-06-29 | — | — | US | disclosed |
| CN-116018405-A | TREM compositions and related methods | 旗舰先锋创新VI有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20230054178-A1 | TREM COMPOSITIONS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-02-23 | — | — | US | disclosed |
| CN-115516090-A | TREM compositions and uses thereof | 旗舰先锋创新VI有限责任公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-1986697-B1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2261334-B1 | Modified polynucleotides for use in RNA interference | THERMO FISHER SCIENT BIOSCIENCES INC (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-1733035-B1 | MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET EFFECTS IN RNA INTERFERENCE | DHARMACON INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8362203-B2 | Non-natural peptides as models for the development of antibiotics | WAYNE STATE UNIVERSITY (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012023152-A3 | MULTI-PROCESSOR ELECTRONIC SYSTEMS | INEDA SYSTEMS PVT. LTD (IN) | 2012-05-10 | — | — | WO | disclosed |
| WO-2007106413-A2 | EXTENDED LENGTH BORANE PHOSPHONATE NUCLEIC ACID COMPOUNDS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007095387-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070173476-A1 | MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE | DHARMACON INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070167384-A1 | Modified polynucleotides for use in rna interference | DHARMACON, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20060223777-A1 | Highly functional short hairpin RNA | DHARMACON, INC. | 2006-10-05 | — | — | US | disclosed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050223427-A1 | Modified polynucleotides for reducing off-target effects in RNA interference | DHARMACON, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050176045-A1 | SNP discriminatory siRNA | DHARMACON, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054178-A1 | TREM COMPOSITIONS AND USES THEREOF | TRMT1, TARBP1, TRMT1L | IDO1 1319/4885TDO2 638/4885IDO2 1345/4885 |
| US-20070167384-A1 | Modified polynucleotides for use in rna interference | PHAX, NSUN2, RNMT | IDO1 4501/4885TDO2 3693/4885IDO2 4328/4885 |
| US-20070173476-A1 | MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE | PHAX, NSUN2, RNMT | IDO1 4501/4885TDO2 3693/4885IDO2 4328/4885 |
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | TRMT1, TARBP1, TRMT1L | IDO1 1319/4885TDO2 638/4885IDO2 1345/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | IDO1 1522/4885TDO2 2903/4885IDO2 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.